Welcome to Jianke online pharmacy! Sign in Free registration
reminder:The pictures are the real photos of the original products taken by Jianke for reference only; In case of new packaging listing, there may be update lag, please take the physical object as the standard!
Baidu certification

Valsartan amlodipine tablets (Ⅰ) (beibote)

Treatment of essential hypertension. This product is used for single drug treatment of patients who can not fully control blood pressure. More role
App download minus 10 yuan
Common name:
Valsartan amlodipine tablets (Ⅰ)
Product No.:
B14202012034
Approval No.:
Gyzz j20150135 (inquired by the State Drug Administration)
Jianke price:
¥68.50
Product specification:
(80mg+5mg)*7s
Manufacturer:
Novartis pharmaceuticas. A. (Spain) (sub packaged by Beijing Novartis Pharmaceutical Co., Ltd.)
number        Quantity:
Add to list
Tips:
This product is a prescription drug. Please buy it with the prescription paper; Delivered by Jianke offline drugstore
 
(for assistance, please call400-086-5111
Jianke promises:
Genuine guarantee
Bank remittance / transfer online payment
  • Product introduction
  • instructions
  • Qualification certificate
  • Relevant information
Product name Valsartan amlodipine tablets (Ⅰ) (beibote)
Main raw materials This product is a compound preparation, and its components are: each tablet contains 80 mg of valsartan and 5 mg of amlodipine.
Main role Treatment of essential hypertension. This product is used for single drug treatment of patients who can not fully control blood pressure.
Product specification (80mg+5mg)*7s
Usage and dosage Amlodipine 2.5-10 mg once daily is effective in the treatment of hypertension, while the effective dose of valsartan is 80-320 mg. In the clinical trial of once daily valsartan and amlodipine tablets, amlodipine 5-10 mg and valsartan 80-320 mg were used, and the antihypertensive effect increased with the increase of dose. 1. For patients who cannot fully control blood pressure with single drug treatment, beibote can be used instead. 2. Additional treatment: when amlodipine monotherapy or valsartan monotherapy is used, patients who fail to fully control blood pressure can be treated with beibotte. 3. Patients with dose limiting adverse reactions during single drug treatment of amlodipine or valsartan can switch to beibotte and use a lower dose of single drug component combined with another component to achieve the effect of blood pressure control. 4. Alternative treatment: in order to facilitate administration, patients receiving amlodipine and valsartan monotherapy can be treated with the same dose of beibotte. (see the inner package manual for details)
manufacturing enterprise Novartis pharmaceuticas. A. (Spain) (sub packaged by Beijing Novartis Pharmaceutical Co., Ltd.)
Jianke commitment
  • Genuine guarantee, formal invoice

    Jianke.com is an approved (B2C) Internet drug legitimate business enterprise in Guangdong Province. It signs a direct supply agreement with the manufacturer and can issue formal invoices for the purchased goods.

  • Private packaging, privacy protection

    When jianke.com packages and delivers goods, the appearance of the packing box only displays the necessary information for delivery, and the name of the purchased goods will not appear. The specific shopping list is in the package to protect the privacy of customers.

  • Efficient logistics and safe arrival

    All products of jianke.com adopt the door-to-door distribution mode of third-party logistics. They are delivered to the nearest warehouse according to your distribution address, so as to deliver them to you on time.

  • Three warehouses to ensure inventory

    Jianke.com has three warehouses in Guangzhou, Dongguan and Wuhan, equipped with first-class equipment, constant temperature and humidity to ensure drug quality. Specially assigned person to manage and ensure product inventory.

[drug name] Valsartan amlodipine tablets (Ⅰ) (beibote)

[common name] Valsartan amlodipine tablets (Ⅰ)

[specification and model] (80mg+5mg)*7s

[manufacturer] Novartis pharmaceuticas. A. (Spain) (sub packaged by Beijing Novartis Pharmaceutical Co., Ltd.)

[drug type] Western medicine

[approval No.] Gyzz j20150135

[validity period] 36 months

[functional indications] Treatment of essential hypertension. This product is used for single drug treatment of patients who can not fully control blood pressure.

[usage and dosage] Amlodipine 2.5-10 mg once daily is effective in the treatment of hypertension, while the effective dose of valsartan is 80-320 mg. In the clinical trial of once daily valsartan and amlodipine tablets, amlodipine 5-10 mg and valsartan 80-320 mg were used, and the antihypertensive effect increased with the increase of dose. 1. For patients who cannot fully control blood pressure with single drug treatment, beibote can be used instead. 2. Additional treatment: when amlodipine monotherapy or valsartan monotherapy is used, patients who fail to fully control blood pressure can be treated with beibotte. 3. Patients with dose limiting adverse reactions during single drug treatment of amlodipine or valsartan can switch to beibotte and use a lower dose of single drug component combined with another component to achieve the effect of blood pressure control. 4. Alternative treatment: in order to facilitate administration, patients receiving amlodipine and valsartan monotherapy can be treated with the same dose of beibotte. (see the inner package manual for details)

[adverse reactions] The safety of this product was evaluated in 5 controlled clinical trials. A total of 5175 patients participated in the trial, of which 2613 cases were treated with valsartan and amlodipine. The safety of valsartan amlodipine tablets has been evaluated in more than 2600 patients with hypertension; Among them, more than 1440 patients received treatment for more than 6 months and more than 540 patients received treatment for more than 1 year. Adverse reactions are usually mild and transient, and drug withdrawal is required in very few cases. The overall incidence of adverse reactions was dose independent and independent of gender, age and race. In the placebo-controlled clinical study, 1.8% of patients in the Valsartan amlodipine tablet treatment group stopped taking drugs due to side effects, compared with 2.1% in the placebo group. The most common reasons for drug withdrawal were peripheral edema (0.4%) and vertigo (0.2%). In the placebo-controlled clinical trial, at least 2% of patients treated with this product had adverse reactions, and the incidence in the Valsartan amlodipine tablet group (n = 1437) was higher than that in the placebo group (n = 337). The adverse reactions were peripheral edema (5.4% vs. 3.0%), nasopharyngitis (4.3% vs. 1.8%), upper respiratory tract infection (2.9% vs. 2.1%) and dizziness (2.1% vs. 0.9%). Less than 1% of patients had postural events (orthostatic hypotension and postural dizziness). In the placebo-controlled clinical trial, other adverse reactions (≥ 0.2%) in the Valsartan amlodipine tablet group are listed below. It is uncertain whether these adverse reactions are caused by this product. (see the inner package manual for details)

[precautions] 1. Hypotension: in the placebo-controlled trial, 0.4% of patients with uncomplicated hypertension treated with valsartan amlodipine tablets had excessive hypotension. Symptomatic hypotension may occur when patients with active renin-angiotensin system (such as patients with high-dose diuretics, insufficient blood volume and / or salt) receive angiotensin II receptor antagonists. It is recommended to correct the condition of insufficient blood volume before taking this product, or conduct close clinical monitoring at the beginning of treatment. Care should be taken when starting treatment in patients with heart failure or recent myocardial infarction and patients undergoing surgery or dialysis. Valsartan given to patients with heart failure or myocardial infarction usually causes a decrease in blood pressure, but if the dosing instructions are followed, it is usually not necessary to stop treatment due to persistent symptomatic hypotension. In the controlled clinical trial of patients with heart failure, the incidence of hypotension in patients treated with valsartan was 5.5% and 1.8% in the placebo group. In the Valsartan acute myocardial infarction trial (VALIANT), the proportion of patients with permanent withdrawal due to hypotension after myocardial infarction was 1.4% in the valsartan treatment group and 0.8% in the captopril treatment group. 2. Increased risk of myocardial infarction or angina pectoris: it is rare for patients (especially in patients with severe obstructive coronary artery disease) to increase the frequency, duration or severity of angina pectoris or acute myocardial infarction when they begin to receive calcium channel blocker treatment or increase the dose. The mechanism of this effect is unclear. 3. Liver function injury. 4. Study on amlodipine: amlodipine is widely metabolized through the liver. In patients with liver function injury, the plasma clearance half-life (T1 / 2) is 56 hours. Therefore, patients with severe liver function injury should use amlodipine with caution. 5. Study on valsartan: Valsartan is mainly cleared by bile. In patients with mild to moderate chronic liver disease, including patients with biliary obstruction disease, the average exposure of valsartan (calculated by AUC value) is twice that of healthy volunteers (age, gender and weight matching). Patients with liver disease or biliary obstruction should use this product with caution. (see the instructions inside the package for details) please read the instructions carefully and follow the doctor's advice.

[taboo] It is forbidden for those who are allergic to the active ingredients or any excipients of this product. It is forbidden for pregnant and lactating women (see [medication for pregnant and lactating women]). At present, there is no medication data for patients with severe renal function injury (creatinine clearance rate < 10 ml / min). This product should be banned in patients with hereditary angioedema and patients who develop angioedema in the early stage of treatment with ACE inhibitors or angiotensin II receptor antagonists.

[listing Permit Holder] Novartis pharmaceuticas. A. (Spain)

[packaging unit] box

[main ingredients] This product is a compound preparation, and its components are: each tablet contains 80 mg of valsartan and 5 mg of amlodipine.

[character] This product is film coated tablets. The film coated tablets appear white after removal.

[applicable population] Adult, elderly

[medication for pregnant and lactating women] Women of childbearing age: as a drug directly acting on renin angiotensin aldosterone (RAAS), exforge should be prohibited for women preparing for pregnancy. When the prescription of drugs acting on RAAS is involved in the prescription of professionals in medical institutions, women of childbearing age should be informed of the possible hazards of taking these drugs during pregnancy. Pregnancy: as a drug directly acting on RAAS, pregnant women ([contraindication]) should prohibit this product. In view of the mechanism of action of angiotensin II antagonist, its harm to the fetus cannot be ruled out. It has been reported that in the second and third trimesters of pregnancy, intrauterine administration of angiotensin converting enzyme inhibitors (a specific class of drugs acting on RAAS) will cause damage to the developing fetus or cause fetal death. In addition, in the retrospective data, there is a potential risk of congenital defects in the use of angiotensin converting enzyme inhibitors in the first 3 months of pregnancy. There have been reports of spontaneous abortion, oligohydramnios and neonatal renal insufficiency when pregnant women inadvertently take valsartan. Similar to other drugs directly acting on RAAS, this product should not be used by pregnant women (see [contraindication]). For women of childbearing age, when prescribing drugs acting on RAAS, doctors should inform them of the potential risks of such drugs during pregnancy. If pregnancy is found during medication, stop this product immediately. There are insufficient clinical data on the use of amlodipine in pregnant women. Animal studies of amlodipine showed reproductive toxicity when the dose was 8 times the maximum recommended dose of 10mg (see [pharmacology and toxicology]). The possible risks to people are unknown.

[medication for children] The safety and efficacy of this product in child patients have not been determined.

[medication for elderly patients] In the controlled clinical study, 323 (22.5%) patients with hypertension treated with this product were ≥ 65 years old, and 79 (5.5%) patients were ≥ 75 years old. No overall difference was observed in the efficacy and safety of this product in this patient population, but it does not rule out that some elderly patients are more sensitive to drugs. Amlodipine: in the study of amlodipine besylate tablets, the number of subjects aged 65 and over is insufficient, and it is uncertain whether their drug response is different from that of young subjects. No different responses were found between elderly and young patients in other clinical experience. Generally speaking, it is necessary to carefully select the dosage of drugs in elderly patients. Generally, starting from the lowest dose, elderly patients have a high incidence of decreased liver, kidney and heart function, and are often accompanied by other diseases or receiving other drug treatment. The clearance rate of amlodipine in elderly patients is reduced, resulting in an increase of AUC of about 40-60%. Therefore, when the elderly use amlodipine, they usually start treatment with a lower starting dose of 2.5mg/day. Valsartan: in the controlled clinical study of valsartan, 1214 (36.2%) patients with hypertension treated with valsartan were 65 years old or older, and 265 (7.9%) patients were 75 years old or older. In this patient population, no overall difference in the efficacy or safety of valsartan was observed, but it does not rule out that some elderly individuals are more sensitive to drugs.

[storage] Sealing, below 30 degrees.

Praise degree

zero%

    reminder

    Dear customer:

    In case of emergency, please call the ordering hotline400-086-5111Consult a health care professional pharmacist.

    Valsartan amlodipine tablets (Ⅰ) (beibote)

    ¥68.50

    reminder

    To ensure your privacy, please enter the verification code and click "confirm callback". Our customer service staff will call back the phone number you entered later!

    Please enter the correct verification code!
    Loding...
    Can't see clearly. Change one

    Dear customer:

    Your callback failed this time. Please re-enter the verification code to try. Thank you!